UK secures agreement for 30m doses of drug being developed by BioNTech and Pfizer and a deal in principle for 60m doses of one by Valneva
Here is a statement from Prof Sarah Gilbert, professor of vaccinology at Oxford University and head of the team working on the Oxford coronavirus vaccine, on the early trial results. She said: There is still much work to be done before we can confirm if our vaccine will help manage the Covid-19 pandemic, but these early results hold promise.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Russia claims to have signed Covid-19 vaccine deal with Oxford UniKirill Dmitriev, head of Russia's sovereign wealth fund, pictured right said Moscow has signed a deal to produce a Covid-19 vaccine with Oxford University.
Read more »
Russia claims to have signed Covid-19 vaccine deal with Oxford UniKirill Dmitriev, head of Russia's sovereign wealth fund, pictured right said Moscow has signed a deal to produce a Covid-19 vaccine with Oxford University.
Read more »
Russia claims to have signed Covid-19 vaccine deal with Oxford UniKirill Dmitriev, head of Russia's sovereign wealth fund, pictured right said Moscow has signed a deal to produce a Covid-19 vaccine with Oxford University.
Read more »
Coronavirus: UK secures early access to 90 million COVID-19 vaccine dosesBREAKING: The UK has secured early access to 90 million COVID19 vaccine doses through partnerships with pharmaceutical companies. Read more here:
Read more »
UK secures early access to 90 million coronavirus vaccine dosesTHE UK has secured early access to 90 million coronavirus vaccine doses currently undergoing Phase 2 trials with pharmaceutical companies. A third of the Covid-19 treatments are being jointly devel…
Read more »
UK signs deal for early access to 90,000,000 doses of new coronavirus vaccineThe deal ‘ensures the UK has the best chance possible of securing a vaccine that protects those most at risk’ 🙏
Read more »